LKL International Berhad: Detailed Analysis of Proposed Renewal of Shareholders’ Mandate for RRPT

Introduction

LKL International Berhad (“LKL” or “the Company”) has issued a circular to shareholders detailing its intention to renew the existing shareholders’ mandate for recurrent related party transactions (“RRPTs”) of a revenue and/or trading nature. This renewal will be tabled for approval as Special Business at the Eleventh Annual General Meeting (11^th AGM) scheduled for 29 May 2026. This article provides an in-depth review of the proposal, its implications, and key items investors should be aware of.

Key Highlights of the Circular

• Nature of Mandate: The mandate concerns RRPTs that are necessary for the day-to-day operations of the LKL Group, specifically transactions with related parties such as Bioalpha Holdings Berhad (“Bioalpha Group”). These transactions are to be conducted at arm’s length and on normal commercial terms.
• Annual Renewal: The mandate is subject to annual renewal. Disclosure of aggregate values of such transactions will be made in the annual report if thresholds are exceeded.
• Validity: If approved, the mandate will last until the next AGM or until revoked/varied by shareholders.
• Approval and Voting: Interested Directors, Major Shareholders and persons connected to them must abstain from voting on the resolution. Proxy voting is available for shareholders unable to attend.
• Principal Activities: LKL Group operates in medical/healthcare beds, hospital furniture, medical equipment, pharmaceuticals, property development, and general trading.
• Material RRPTs: The contemplated RRPTs include sales and purchases of pharmaceutical products, medical and healthcare equipment, and service charges related to pharmacy business with Bioalpha Group. Estimated values for these transactions during the mandate period are RM8 million (sales), RM3 million (purchases), and RM2 million (management/service charges).
• Review Procedures: RRPTs are subject to internal review, approval thresholds, and oversight by the Audit and Risk Management Committee (ARMC) to ensure fairness and prevent detriment to minority shareholders.
• Disclosure and Transparency: All RRPTs will be disclosed in the annual report with breakdowns by transaction type, related party, and relationship to LKL.
• Rationale: The mandate avoids the need for frequent AGMs for RRPT approval, enables operational efficiency, and leverages related parties’ expertise in healthcare.
• Material Contracts: Recent material contracts include a RM24 million property acquisition and a RM4.8 million pharmacy business acquisition, both completed in 2024-2025.
• Material Litigation: Noteworthy litigation includes recovery of RM2 million from Manico New Impact Sdn. Bhd. (now wound up), and a resolved defamation suit against The Edge Communications Sdn. Bhd.
• No Outstanding Amounts: As of the latest practicable date, there are no overdue sums from related parties exceeding credit terms.
• Shareholder Interests: Botanical Distribution is a major shareholder (14.69%), with Bioalpha as its holding company. Tan Su Ning (Independent Non-Executive Director) sits on the boards of both LKL and Bioalpha.
• No Material Financial Impact: The mandate is not expected to affect share capital, dividends, shareholdings, net assets, gearing, or earnings in any material way.

Potential Price Sensitive and Investor-Relevant Information

• Large RRPT Estimates: The aggregate RRPTs with Bioalpha Group could reach up to RM13 million during the mandate period. If actual values exceed estimates by 10% or more, immediate disclosure to Bursa Malaysia is required. This could signal increased business activity or unexpected changes in related party dealings.
• Material Contracts Completed: Substantial property and pharmacy business acquisitions may impact the Group’s future earnings, asset base, and strategic direction.
• Litigation Outcomes: The successful recovery of RM2 million and conclusion of defamation litigation remove potential liabilities and uncertainties for LKL.
• Governance and Oversight: The robust review mechanisms and ARMC oversight may reassure investors regarding the integrity of RRPTs, mitigating risks of related party abuses.
• Shareholder Abstentions: Major shareholders and directors with interests in Bioalpha and Botanical Distribution will abstain from voting, reducing conflict-of-interest risks but highlighting their involvement in RRPTs.
• Strategic Partnerships: RRPTs with Bioalpha Group offer LKL access to pharmaceutical and healthcare expertise, potentially supporting revenue growth in these segments.

Summary for Investors

The Proposed Renewal of Existing Shareholders’ Mandate for RRPTs is a routine but significant corporate action for LKL International Berhad. While the mandate itself is not expected to have direct material impact on share capital or earnings, the scale of RRPTs, completed acquisitions, and successful litigation outcomes could influence investor sentiment and future business prospects. Active engagement with Bioalpha Group and related parties may support growth, but also requires ongoing vigilance to ensure fairness and transparency.

Shareholders should monitor RRPT disclosures, AGM outcomes, and any Bursa Malaysia announcements for actual RRPT values exceeding estimates, as these could be price sensitive. The Group’s commitment to rigorous governance, conflict-of-interest management, and transparency may mitigate risks but also underscores the importance of related party business to LKL’s operations.

Disclaimer

This article is intended for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. All information is based on the official circular and publicly available documents. Investors are advised to conduct their own research and consult professional advisors before making investment decisions. The author assumes no responsibility for any losses or damages arising from reliance on the information provided herein.

View LKL INTERNATIONAL BERHAD Historical chart here